1-8 of 8
Brigitt E. Abbuehl, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Eric S. Mullins, MD, Christine M. Knoll, MD, Amy L. Dunn, MD, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2016) 128 (22): 1409.
https://doi.org/10.1182/blood.V128.22.1409.1409
Published: 2016
Journal Articles

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Amy L. Dunn, MD, Alexis A. Thompson, MD MPH, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2016) 128 (22): 3778.
https://doi.org/10.1182/blood.V128.22.3778.3778
Published: 2016
Journal Articles

Target Joint Status in Patients with Hemophilia a during 18 Consecutive Months of Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2016) 128 (22): 2592.
https://doi.org/10.1182/blood.V128.22.2592.2592
Published: 2016
Journal Articles

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

Frank Michael Horling, PhD, Peter Allacher, PhD, Herwig Koppensteiner, PhD, Werner Engl, PhD Cstat, Fritz Scheiflinger, PhD, Brigitt E. Abbuehl, MD, Birgit M Reipert, PhD
Journal: Blood
Blood (2016) 128 (22): 2594.
https://doi.org/10.1182/blood.V128.22.2594.2594
Published: 2016
Journal Articles

An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Dyck-Jones Jacqueline, PhD, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2016) 128 (22): 3801.
https://doi.org/10.1182/blood.V128.22.3801.3801
Published: 2016
Journal Articles

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

Jerzy Windyga, MD, Toshko Jelev Lissitchkov, MD, Vasily Mamonov, MD, Miranda Chapman, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2016) 128 (22): 2585.
https://doi.org/10.1182/blood.V128.22.2585.2585
Published: 2016
Journal Articles

Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B.

Jerzy Windyga, MD, PhD, Toshko Lissitchkov, MD, PhD, Oleksandra Stasyshyn, MD, Vasily Mamonov, MD, Luminita Rusen, MD, PhD, José Luis Lamas, MD, Myungshin Oh, PhD, Miranda Chapman, Sandor Fritsch, PhD, Borislava G Pavlova, PhD, Wing Yen Wong, MD, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2012) 120 (21): 2222.
https://doi.org/10.1182/blood.V120.21.2222.2222
Published: 2012
Journal Articles

Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).

Gerald Spotts, PhD, Brigitt E. Abbuehl, MD, Huong D. Luu, PharmD, Clara K. Song, PharmD, Jacqueline A. Dyck-Jones, Norma Guzman-Becerra, LieLing Wu, MyungShin Oh, Michael Zoerer, Judith Jill V. Sosa, Darby E. Stephens, Linda J. Yamamoto, MD, Bruce M. Ewenstein, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3670.
https://doi.org/10.1182/blood.V116.21.3670.3670
Published: 2010